First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Saadettin Kılıçkap(Istinye University), Ahmet Sezer(Başkent University), Mahmut Gümüş(Istanbul Medeniyet University), Igor Bondarenko(Dnipropetrovsk State Medical Academy), Miranda Gogishvili, Marina Nechaeva(International Institute of Management Arkhangelsk), Michael Schenker, İrfan Çiçin(Trakya University), Gwo Fuang Ho(University of Malaya), Yaroslav Kulyaba, Kasimova Zyuhal(National Institute of Emergency Medicine "Pirogov"), Roxana-Ioana Scheusan, Marina Chiara Garassino(University of Chicago), Xuanyao He(Regeneron (United States)), Manika Kaul(Regeneron (United States)), Emmanuel Chiebuka Okoye(Regeneron (United States)), Yuntong Li(Regeneron (United States)), Siyu Li(Regeneron (United States)), Jean‐François Pouliot(Regeneron (United States)), Frank Seebach(Regeneron (United States)), Israel Lowy(Regeneron (United States)), Giuseppe Gullo(Regeneron (United States)), Petra Rietschel(Regeneron (United States))
Cited by 94
Abstract
Related Papers
No related papers found
Powered by citation graph analysis